Nonadherence to Primary Prophylaxis against Pneumocystis jirovecii Pneumonia

被引:7
|
作者
Heffelfinger, James D. [1 ]
Voetsch, Andrew C. [1 ]
Nakamura, Glenn V. [1 ]
Sullivan, Patrick S. [2 ]
McNaghten, A. D. [1 ]
Huang, Laurence [3 ,4 ]
机构
[1] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA
[2] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA
[3] Univ Calif San Francisco, HIV AIDS Div, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Div Pulmonary & Critical Care Med, San Francisco, CA 94143 USA
来源
PLOS ONE | 2009年 / 4卷 / 03期
基金
美国国家卫生研究院;
关键词
ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; CARINII PNEUMONIA; UNITED-STATES; DRUG-USE; ADHERENCE; PATIENT; EPIDEMIOLOGY; BIAS; AIDS;
D O I
10.1371/journal.pone.0005002
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Despite the effectiveness of prophylaxis, Pneumocystis jirovecii pneumonia (PCP) continues to be the most common serious opportunistic infection among HIV-infected persons. We describe factors associated with nonadherence to primary PCP prophylaxis. Methodology/Principal Findings: We used 2000-2004 data from the Supplement to HIV/AIDS Surveillance (SHAS) project, a cross-sectional interview project of HIV-infected persons >= 18 years conducted in 18 states. We limited the analysis to persons who denied having prior PCP, reported having a current prescription to prevent PCP, and answered the question "In the past 30 days, how often were you able to take the PCP medication(s) exactly the way your doctor told you to take them?'' We used multivariable logistic regression to describe factors associated with nonadherence. Of 1,666 subjects prescribed PCP prophylaxis, 305 (18.3%) were nonadherent. Persons were more likely to be nonadherent if they reported using marijuana (adjusted odds ratio [aOR] = 1.6, 95% confidence interval [CI] = 1.1-2.4), non-injection drugs other than marijuana (aOR = 1.5, 95% CI = 1.0-2.1), or injection drugs (aOR = 2.3, 95% CI = 1.3-4.1) in the past year; their mental health was "not good'' for >= 1 day during the past month (aOR = 1.6, 95% CI = 1.2-2.2); their most recent CD4 count was,200 cells/mu L (aOR = 1.6, 95% CI = 1.1-2.2); or taking ART usually (aOR = 9.6, 95% CI = 6.7-13.7) or sometimes/rarely/never (aOR = 18.4, 95% CI = 11.1-30.4), compared with always, as prescribed. Conclusion/Significance: Providers should inquire about and promote strategies to improve adherence to PCP prophylaxis, particularly among persons who use illicit drugs, have mental health issues, and who are not compliant with ART to reduce the occurrence of PCP.
引用
下载
收藏
页数:7
相关论文
共 50 条
  • [1] Prophylaxis Against Pneumocystis jirovecii Pneumonia in Adults
    Zhou, Shiwei
    Aitken, Samuel L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (02): : 182 - 183
  • [2] Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab
    Park, Jun Won
    Curtis, Jeffrey R.
    Jun, Kang Il
    Kim, Tae Min
    Heo, Dae Seog
    Ha, Jongwon
    Suh, Kyung-Suk
    Lee, Kwang-Woong
    Lee, Hajeong
    Yang, Jaeseok
    Kim, Min Jung
    Choi, Yunhee
    Lee, Eun Bong
    CHEST, 2022, 161 (05) : 1201 - 1210
  • [3] Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients with Connective Tissue Diseases
    Vananuvat, Passawee
    Suwannalai, Parawee
    Sungkanuparph, Somnuek
    Limsuwan, Ticha
    Ngamjanyaporn, Pintip
    Janwityanujit, Suchela
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2011, 41 (03) : 497 - 502
  • [4] Prescribing rates of pneumocystis jirovecii pneumonia prophylaxis
    Foo, Yun Megan
    Lennon, Tamara
    Chin, Melvin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 180 - 180
  • [5] PRIMARY PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA
    TARABEY, R
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (20): : 1499 - 1499
  • [6] Pneumocystis jirovecii Pneumonia in Neurologic Disorders Is Prophylaxis Necessary?
    Pike-Lee, Tiffany
    Syed, Sana
    Willis, Mary Alissa
    Li, Yuebing
    NEUROLOGY-CLINICAL PRACTICE, 2021, 11 (03) : 242 - 248
  • [7] Should prophylaxis against Pneumocystis jirovecii pneumonia be considered in selected patients with leprosy reactions?
    Ramirez-Perea, Nuria
    Moran-Castano, Claudia
    Perez-Molina, Jose A.
    PNEUMONIA, 2024, 16 (01)
  • [8] Should prophylaxis against Pneumocystis jirovecii pneumonia be considered in selected patients with leprosy reactions?
    Nuria Ramírez-Perea
    Claudia Moran-Castaño
    Jose A. Perez-Molina
    Pneumonia, 16
  • [9] Prophylaxis against Pneumocystis jirovecii pneumonia in adults (vol 330, pg 182, 2023)
    Zhou, S.
    Aitken, S. L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (13): : 1289 - 1289
  • [10] Prophylaxis Against Pneumocystis Pneumonia
    Caplan, Avrom S.
    Mecoli, Christopher A.
    Micheletti, Robert G.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (19): : 1908 - 1909